ICU Medical (NASDAQ:ICUI) Reaches New 12-Month High at $167.38

Shares of ICU Medical, Inc. (NASDAQ:ICUI) hit a new 52-week high during trading on Monday . The stock traded as high as $167.38 and last traded at $167.38, with a volume of 65258 shares trading hands. The stock had previously closed at $162.32.

Wall Street Analyst Weigh In

ICUI has been the subject of several research analyst reports. Raymond James raised their target price on shares of ICU Medical from $135.00 to $158.00 and gave the company an “outperform” rating in a research note on Thursday, August 8th. KeyCorp lifted their price target on shares of ICU Medical from $136.00 to $147.00 and gave the stock an “overweight” rating in a research note on Thursday, August 8th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of ICU Medical in a report on Thursday, August 8th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $138.33.

ICU Medical Price Performance

The stock’s 50-day moving average price is $141.09 and its 200 day moving average price is $117.67. The firm has a market capitalization of $4.16 billion, a price-to-earnings ratio of -67.79 and a beta of 0.65. The company has a quick ratio of 1.08, a current ratio of 2.41 and a debt-to-equity ratio of 0.76.

ICU Medical (NASDAQ:ICUI) last posted its quarterly earnings data on Wednesday, August 7th. The medical instruments supplier reported $1.56 EPS for the quarter, beating the consensus estimate of $1.00 by $0.56. The business had revenue of $596.50 million during the quarter, compared to analyst estimates of $556.64 million. ICU Medical had a negative net margin of 3.07% and a positive return on equity of 5.01%. The business’s revenue for the quarter was up 8.6% compared to the same quarter last year. During the same quarter last year, the firm posted $1.58 earnings per share. Equities research analysts expect that ICU Medical, Inc. will post 3.76 earnings per share for the current fiscal year.

Insider Transactions at ICU Medical

In related news, CEO Vivek Jain sold 12,000 shares of the stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $163.46, for a total value of $1,961,520.00. Following the sale, the chief executive officer now directly owns 104,593 shares of the company’s stock, valued at approximately $17,096,771.78. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, CEO Vivek Jain sold 12,000 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $163.46, for a total transaction of $1,961,520.00. Following the completion of the sale, the chief executive officer now owns 104,593 shares of the company’s stock, valued at approximately $17,096,771.78. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Daniel Woolson sold 2,502 shares of the stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $163.22, for a total transaction of $408,376.44. Following the completion of the sale, the vice president now directly owns 13,107 shares of the company’s stock, valued at approximately $2,139,324.54. The disclosure for this sale can be found here. Insiders have sold a total of 28,552 shares of company stock valued at $4,537,802 in the last ninety days. 6.70% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On ICU Medical

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its holdings in shares of ICU Medical by 14.8% in the fourth quarter. Vanguard Group Inc. now owns 2,440,729 shares of the medical instruments supplier’s stock valued at $243,438,000 after purchasing an additional 315,103 shares in the last quarter. Norges Bank purchased a new stake in shares of ICU Medical in the fourth quarter valued at $20,669,000. The Manufacturers Life Insurance Company raised its holdings in shares of ICU Medical by 539.1% during the fourth quarter. The Manufacturers Life Insurance Company now owns 177,009 shares of the medical instruments supplier’s stock worth $17,655,000 after acquiring an additional 149,313 shares in the last quarter. Silvercrest Asset Management Group LLC raised its holdings in shares of ICU Medical by 109.4% during the first quarter. Silvercrest Asset Management Group LLC now owns 278,436 shares of the medical instruments supplier’s stock worth $29,882,000 after acquiring an additional 145,485 shares in the last quarter. Finally, Mesirow Institutional Investment Management Inc. purchased a new stake in shares of ICU Medical during the first quarter worth $15,425,000. 96.10% of the stock is owned by institutional investors.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.